NSCLC tissues; normal adjacent tissue; serum; serum exosomes
HBE; A549; PC9; H1650; H1299; THP-1
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); stemness (promotes); glycolysis (promotes); HIF-1 signaling (promotes); macrophage polarization (promotes); immune regulation (other); ceRNA regulation (promotes); metastasis (promotes)
RT-qPCR; RNase R Treatment; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; FISH / smFISH; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Flow Cytometry(Non-apoptosis/cycle); In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); IF (Immunofluorescence); ROC Analysis; Survival Analysis; Bioinformatics Analysis
Serum exosomal circSHKBP1 shows diagnostic value for NSCLC (AUC=0.853) and its expression levels are related to lymphatic metastasis and TNM stage; overexpression is associated with poor prognosis.
circSHKBP1 (hsa_circ_0000936), enriched in NSCLC-derived exosomes, is upregulated in NSCLC and promotes proliferation, migration/invasion, stemness, glycolysis, and in vivo tumor growth/metastasis. Mechanistically, it sponges miR-1294 to upregulate PKM2 and activate PKM2/HIF-1alpha-dependent glycolysis, fostering M2 macrophage polarization/recruitment and suppressing CD8+ T-cell cytokine secretion. Serum exosomal circSHKBP1 shows potential diagnostic value and correlates with advanced disease features and poor prognosis.
0.8818
Exosomal circSHKBP1 participates in non-small cell lung cancer progression through PKM2-mediated glycolysis.
combined biological and clinical study